Novartis division Alcon has introduced the minimally invasive glaucoma surgical device, CyPass Micro-Stent in the US.

The prescription medical device is implanted during cataract surgery below the surface of the eye, into the supraciliary space.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has been designed to lower intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma by increasing aqueous outflow through one of the natural drainage pathways of the eye, ensuring minimal tissue disruption, which allows the excess fluid in the eye to drain.

"Over 60 million people globally are affected by glaucoma that can lead to progressive damage of the optic nerve."

Alcon North America president Sergio Duplan said: "We are excited to launch the CyPass Micro-Stent device in a new segment of glaucoma treatment called minimally-invasive glaucoma surgery, or MIGS.

"This new treatment option for cataract patients with mild to moderate primary open-angle glaucoma has been demonstrated to have a lasting, significant IOP-lowering effect."

The CyPass Micro-Stent was developed by Transcend Medical, which Alcon acquired in February this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Over 60 million people globally are affected by glaucoma that can lead to progressive damage of the optic nerve.

Early diagnosis of glaucoma is critical to manage the disease, as it is often asymptomatic and therefore can go undetected until it is at an advanced stage.

As the disease progresses, patients may experience loss of peripheral (side) vision, tunnel vision or eye spots.

Glaucoma can lead to gradual, irreversible loss of vision and blindness.

The exact cause of glaucoma is unknown.